You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

Filter Results

Select search scope: search across all journals or within the current journal

Search this journal

Enter search terms…

Advanced search

Browse

About

About Sage
About Sage Journals
Privacy Policy
Terms of Use
Contact Us
Help

Information for

Authors
Editors
Librarians
Researchers
Reviewers
Frequently asked questions

All content on this site: Copyright © 2026 Sage Publications. All rights reserved. This website is technically supported and operated by China National Publications Import and Export (Group) Co., Ltd. 京ICP备09090397号-11

Comment: Bioavailability and Safety of Two Ceftriaxone Formulations — Exposure to Lidocaine Questioned

Annals of Pharmacotherapy

Impact Factor: 2.3 / 5-Year Impact Factor: 2.7

Journal Homepage Submission guidelines

Restricted access

Letter

First published online April, 1997

Comment: Bioavailability and Safety of Two Ceftriaxone Formulations — Exposure to Lidocaine Questioned

, , and

Volume 31, Issue 4

https://doi.org/10.1177/106002809703100425

Abstract

Get full access to this article

View all access options for this article.

References

Suárez

E.C.

, Grippi

J.R.

. Comparative bioavailability and safety of two intramuscular ceftriaxone formulations. Ann Pharmacother 1996; 30: 1223–6.

Bradley

J.S.

, Compiogiannis

L.S.

, Murray

W.E.

, Acosta

M.A.

, Tsu

G.L.

. Pharmacokinetics and safety of intramuscular injection of concentrated ceftriaxone in children. Clin Pharm 1992; 11: 961–4.

Browse journal

Current issue OnlineFirst All issues

Similar articles

Retricted access

Degeneration and Dysfunction of Retinal Neurons in Acute Ocular Hypertensive Rats: Involvement of Calpains

Retricted access

i Drugs and i Devices Discovery Research: Preclinical Assays,Techniques,and Animal Model Studies for Ocular Hypotensives and Neuroprotectants

Retricted access

Eyes on New Product Development

Retricted access

The Effects of Commercially Available Preservative-Free FDA-Approved Triamcinolone (Triesence ® ) on Retinal Cells in Culture